Pluristem Therapeutics

$6.10
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.43 (-6.38%) Today
-$0.21 (-3.33%) As of 1:30 PM UTC after-hours

Why Robinhood?

You can buy or sell PSTI and other stocks, options, and ETFs commission-free!

About PSTI

Pluristem Therapeutics, Inc. Common Stock, also called Pluristem Therapeutics, is a clinical stage company, which engages in cell therapy development. It develops placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The firm focuses on the development, clinical trials and manufacturing of cell therapeutics and related technologies. Its products include Clinical Pipeline, PLX-Immune, PLX-PAD, and PLX-R18. The company was founded by Doron Shorrer on May 11, 2001 and is headquartered in Haifa, Israel. The listed name for PSTI is Pluristem Therapeutics, Inc. Common Stock.

CEO
Yaky Yanay
Employees
146
Headquarters
Haifa, Haifa
Founded
2001
Market Cap
191.28M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
819.71K
High Today
$6.87
Low Today
$6.04
Open Price
$6.62
Volume
425.10K
52 Week High
$13.29
52 Week Low
$2.82

PSTI Earnings

-$2.66
-$1.77
-$0.89
$0.00
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Q2 FY21
Q3 FY21
Estimated
— per share
Actual
Expected May 10, After Hours

You May Also Like

BLDR
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure